(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/176273 A8

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61K 9/28* (2006.01)
A61K 9/20 (2006.01) *A61K 31/00* (2006.01)

(21) International Application Number:
PCT/IB2021/000115

(22) International Filing Date:
03 March 2021 (03.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2020-037177 04 March 2020 (04.03.2020) JP

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors: **SUEHARA, Tetsuya**; C/o Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka-shi, Osaka, 532-8686 (JP). **HOHOKABE, Miyuki**; C/o Takeda Pharmaceutical Company Limited, 2-26-1, Muraokahigashi, Fujisawa-shi, Kanagawa-ken, 251-8555 (JP). **HARADA, Kazuki**; C/o Spera Pharma Inc., 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka-shi, Osaka, 532-0024 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
20 October 2022 (20.10.2022)

(15) Information about Correction:
see Notice of 20 October 2022 (20.10.2022)

(54) Title: ORAL SOLID PREPARATIONS

(57) Abstract: Disclosed herein are oral solid preparations comprising a D-ammo acid oxidase (DA AO) inhibitor, a low-substituted hydroxypropyi cellulose (L-HPC), and an additive, wherein the DAAO inhibitor is a pyridazinone derivative, methods for producing the same, and methods of using the same m the prevention or treatment of diseases preventable or treatable using DAAO inhibitors.

WO 2021/176273 A8